Biotech

ContraFect priced its upcoming public offering of common stock and warrants at $40 million.

ContraFect (NASDAQ:CFRX) priced its upcoming public offering of common stock and warrants at $40 million.
As quoted in the press release:

The pricing of its underwritten public offering of 32,000,000 shares of its common stock and related warrants to purchase 16,000,000 shares of common stock with an exercise price of $1.55 per share at a combined public offering price of $1.25 per share and related warrant. All shares and warrants in the offering are to be sold by ContraFect. The gross proceeds from the offering will be $40.0 million.
The offering is expected to close on or about July 25, 2017, subject to customary closing conditions.

Click here to read the full press release.

Source: www.marketwired.com

Featured
Amgen today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63 rd American Society of Hematology Annual Meeting & Exposition in Atlanta, Georgia and virtually, from Dec. 11-14, 2021 . "The data being presented at ASH demonstrates Amgen's commitment to reaching more patients with our innovative hematology medicines and improving the patient experience by exploring more ...

- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia and virtually, from Dec. 11-14, 2021 .

"The data being presented at ASH demonstrates Amgen's commitment to reaching more patients with our innovative hematology medicines and improving the patient experience by exploring more convenient administrations for people living with blood cancers," said David M. Reese , M.D., executive vice president of Research and Development at Amgen. "By accelerating the development and delivery of transformative medicines in difficult to treat and vulnerable patient populations, including children and pregnant women, we continue to focus on the relentless pursuit of breakthroughs for blood cancer patients and their families."

read more Show less
ABBVie today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib achieved both primary endpoints of clinical remission a,b and endoscopic response c at week 12. 1 The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60 percent having previously failed two or more ...

ABBVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission a,b and endoscopic response c at week 12. 1 The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60 percent having previously failed two or more biologics. 1 U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. 1

"The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino , M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."

read more Show less
Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company if they received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to BMS' acquisition of Celgene on November 20, ...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE:BMY), if they received Contingent Value Rights ("CVRs") in exchange for their shares of Celgene Corporation pursuant to BMS' acquisition of Celgene on November 20, 2019. These actions are pending in the United States District Court for the Southern District of New York

What You May Do

read more Show less

MARKETS

Markets
TSX21077.35-85.30
TSXV924.67+4.12
DOW35754.75+35.32
S&P 5004701.21+14.46
NASD15786.99+100.07
ASX7313.90+68.80

COMMODITIES

Commodities
Gold1783.51-1.10
Silver22.45-0.07
Copper4.38-0.01
Palladium1858.39+14.42
Platinum960.00+4.00
Oil72.59+0.23
Heating Oil2.27+0.01
Natural Gas3.82+0.01